Jade Biosciences (JBIO) Non Operating Income (2020 - 2026)
Jade Biosciences posted quarterly Non Operating Income of -$9000.0 for Q1 2026, up 99.94% year-on-year from -$4501.4 in Q1 2025, and up 99.93% on a QoQ basis from -$13.8 million in Q4 2025.
Jade Biosciences (JBIO) has 7 years of Non Operating Income data on file, last reported at -$9000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 99.94% year-over-year to -$9000.0; the trailing twelve-month figure through Mar 2026 stood at -$18.2 million (down 12.91% YoY), and the FY2025 full-year result was -$13.8 million, down 72584.21% from the prior year.
- Non Operating Income for Q1 2026 stood at -$9000.0, up from -$13.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.8 million in Q4 2022 and bottomed at -$14.8 million in Q1 2025.
- The 5-year median for Non Operating Income is -$6000.0 (2022), against an average of -$2.2 million.
- The widest annual swing landed in 2023, when Non Operating Income jumped 21950.0%; it then plunged 492733.33% in 2025.
- A 5-year view of Non Operating Income shows it stood at $1.8 million in 2022, then sank by 317.86% to -$3.8 million in 2023, then surged by 65.65% to -$1.3 million in 2024, then tumbled by 950.46% to -$13.8 million in 2025, then surged by 99.93% to -$9000.0 in 2026.
- The last three Non Operating Income figures came in at -$9000.0 (Q1 2026), -$13.8 million (Q4 2025), and -$28000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2025 | -13.78 Mn |
| Sep 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -4.36 Mn |
| Mar 31, 2025 | -14.79 Mn |
| Sep 30, 2024 | -1.31 Mn |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -3.82 Mn |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Sep 30, 2022 | 564,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Mar 31, 2022 | 109,000.00 |
| Dec 31, 2021 | 48,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Sep 30, 2020 | -64,000.00 |
| Jun 30, 2020 | -577,000.00 |